Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markman

Showing results (71-80 of 1,622) with videos related to

Pageof 163
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2011
The use of bevacizumab in the management of ovarian cancer: an argument for single-agent rather than combination therapyM Markman
Oncology|May 11, 2012
Palliation of symptomatic malignant ascites: an (often) unmet needMaurie Markman
Dental Economics - Oral Hygiene|September 1, 1976
What patients don't tell you!S Markman
Dental Economics - Oral Hygiene|August 1, 1976
Angry patients don't payS Markman
Cancer Chemotherapy and Biological Response Modifiers|May 9, 2000
Supportive careM Markman
Drugs|July 24, 2001
Intraperitoneal drug delivery of antineoplasticsM Markman
Trends in Cognitive Sciences|December 15, 2000
Extending the classical view of representationMarkman, Dietrich
Current Oncology Reports|March 20, 2001
Cancer and the Internet: the good, the bad, and the very uglyM Markman
Hematology/Oncology Clinics of North America|September 1, 1988
Chemotherapy in ovarian carcinoma: intravenous or intraperitoneal?M Markman
IRB|July 30, 2004
What must research subjects be told regarding the results of completed randomized trials?Maurie Markman
Pageof 163

Showing results (71-80 of 1,622) with videos related to

Sort By:
Pageof 163
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2011
The use of bevacizumab in the management of ovarian cancer: an argument for single-agent rather than combination therapyM Markman
Oncology|May 11, 2012
Palliation of symptomatic malignant ascites: an (often) unmet needMaurie Markman
Dental Economics - Oral Hygiene|September 1, 1976
What patients don't tell you!S Markman
Dental Economics - Oral Hygiene|August 1, 1976
Angry patients don't payS Markman
Cancer Chemotherapy and Biological Response Modifiers|May 9, 2000
Supportive careM Markman
Drugs|July 24, 2001
Intraperitoneal drug delivery of antineoplasticsM Markman
Trends in Cognitive Sciences|December 15, 2000
Extending the classical view of representationMarkman, Dietrich
Current Oncology Reports|March 20, 2001
Cancer and the Internet: the good, the bad, and the very uglyM Markman
Hematology/Oncology Clinics of North America|September 1, 1988
Chemotherapy in ovarian carcinoma: intravenous or intraperitoneal?M Markman
IRB|July 30, 2004
What must research subjects be told regarding the results of completed randomized trials?Maurie Markman
Pageof 163